SEC Tracker
Get the app
Person · CIK 1239956

Wendell Wierenga

Director at Cytokinetics, Crinetics Pharmaceuticals and Dermata Therapeutics

Earlier: Ciphergen Biosystems

Source: Forms 3, 4, 5 and 144 on SEC EDGAR

Sold on Form 4$1.9M
Noticed on Form 144$1.8M
Bought on Form 4$0
Companies4

Holdings now

As reported after the latest Form 3, 4 or 5 at each company.

How these figures work

Options and RSUs are from the latest filing that lists them; earlier grants may also be held. Holdings can be out of date when a person stops filing.

CompanySecurityHeldShares or unitsAs of
Cytokinetics CYTKCommon StockDirectly35,660Oct 16, 2026 · Filing · EDGAR
Cytokinetics CYTKNon-Qualified Stock Option (Right to Buy)
exercise $77.15, expires May 26, 2036, into Common Stock
Directly4,301May 27, 2026 · Filing · EDGAR
Dermata Therapeutics DRMACommon StockDirectly62,398Oct 6, 2022 · Filing · EDGAR
Dermata Therapeutics DRMAStock Option (Right to Buy)
exercise $2.18, expires Jan 1, 2036, into Common Stock
Directly2,500Jan 2, 2026 · Filing · EDGAR

Sold and noticed by quarter

Wendell Wierenga: dollars sold on Form 4 and noticed on Form 144 per quarter, Q1 2025 to Q4 2026$1.6M$0Q1 2025: $0 noticed on Form 144Q1 2025: $0 sold on Form 4Q2 2025: $0 noticed on Form 144Q2 2025: $0 sold on Form 4Q3 2025: $0 noticed on Form 144Q3 2025: $0 sold on Form 4Q4 2025: $1.5M noticed on Form 144Q4 2025: $1.6M sold on Form 4Q1 2026: $0 noticed on Form 144Q1 2026: $0 sold on Form 4Q2 2026: $266K noticed on Form 144Q2 2026: $302K sold on Form 4Q3 2026: $0 noticed on Form 144Q3 2026: $0 sold on Form 4Q4 2026: $0 noticed on Form 144Q4 2026: $0 sold on Form 4Q1 2025Q3 2025Q1 2026Q3 2026

Sold (Form 4) Noticed (Form 144) Bought (Form 4)

Quarterly totals as a table
QuarterSold (Form 4)Noticed (Form 144)
Q2 2026$302K$266K
Q4 2025$1.6M$1.5M

Planned sales (Form 144) and the sales that followed

Each Form 144 notice of a planned sale, grouped by broker and 10b5-1 plan, with the Form 4 sales we matched to it.

How we match

A Form 144 is a notice of a planned sale by an affiliate. SEC Tracker matches each notice to Form 4 sales by the same person at the same company within 90 days of the notice, up to the shares noticed. The match is our inference, not something either filing states.

Notice dateNoticedPlanned saleOutcomeLinks
Cytokinetics CYTK · Morgan Stanley Smith Barney · 10b5-1 plan adopted May 14, 2025 · 3 notices
May 5, 20264,032 · ~$266KMay 5, 2026Sold as noticed Sold 4,032 at $75.00 on May 5 · $302K Form 4Filing · EDGAR
Dec 22, 202520,000 · ~$1.3MDec 22, 2025Sold as noticed Sold 20,000 at $66.14 on Dec 22 · $1.3M Form 4Filing · EDGAR
Oct 27, 20254,375 · ~$253KOct 27, 2025Sold as noticed Sold 4,375 at $58.68 on Oct 27 · $257K Form 4Filing · EDGAR

Every transaction, by company

Each Form 3, 4 and 5 transaction in plain words, newest first.

How these figures work

Values are shares times the price each filing states; grants, exercises and gifts usually state no price. Held after is what the filing reports was held once the transaction was done, directly or through the named holder.

Cytokinetics CYTK Director · filings 2025 to 2026 · sold $1.9M · $1.8M noticed on Form 144

DateTransactionSharesPriceValueHeld afterSource
Oct 16, 2026Grant or award from the company+97$63.92$6K35,660 directFiling · EDGAR
Jul 15, 2026Grant or award from the company+75$82.62$6K35,563 directFiling · EDGAR
May 27, 2026Grant or award from the company+2,85135,488 directFiling · EDGAR
May 27, 2026Grant or award from the company
Non-Qualified Stock Option (Right to Buy)
+4,3014,301 directFiling · EDGAR
May 5, 2026Option or RSU exercised or converted+4,032$12.40$50K36,669 directFiling · EDGAR
May 5, 2026Sale under a 10b5-1 plan−4,032$75.00$302K32,637 directFiling · EDGAR
May 5, 2026Option or RSU exercised or converted
Non-Qualified Stock Option (Right to Buy)
−4,0320 directFiling · EDGAR
Apr 15, 2026Grant or award from the company+95$65.37$6K32,637 directFiling · EDGAR
Jan 15, 2026Grant or award from the company+98$63.44$6K32,542 directFiling · EDGAR
Dec 22, 2025Option or RSU exercised or converted+20,000$7.61$152K52,444 directFiling · EDGAR
Dec 22, 2025Sale under a 10b5-1 plan−20,000$66.14$1.3M32,444 directFiling · EDGAR
Dec 22, 2025Option or RSU exercised or converted
Non-Qualified Stock Option (Right to Buy)
−20,0000 directFiling · EDGAR
Oct 27, 2025Option or RSU exercised or converted+4,375$10.00$44K36,819 directFiling · EDGAR
Oct 27, 2025Sale under a 10b5-1 plan−4,375$58.68$257K32,444 directFiling · EDGAR
Oct 27, 2025Option or RSU exercised or converted
Non-Qualified Stock Option (Right to Buy)
−4,3750 directFiling · EDGAR
Oct 15, 2025Grant or award from the company+99$62.80$6K32,444 directFiling · EDGAR

Crinetics Pharmaceuticals CRNX Director · filings 2026 to 2026

DateTransactionSharesPriceValueHeld afterSource
Sep 1, 2026Returned to the company−116,146$85.00$9.9M5,925 directFiling · EDGAR
Sep 1, 2026Returned to the company−5,925$85.00$504K0 directFiling · EDGAR
Sep 1, 2026Returned to the company
Stock Option (Right to Buy)
−12,500$61.76$772K0 directFiling · EDGAR
Sep 1, 2026Returned to the company
Stock Option (Right to Buy)
−12,500$61.77$772K0 directFiling · EDGAR
Sep 1, 2026Returned to the company
Stock Option (Right to Buy)
−17,500$64.77$1.1M0 directFiling · EDGAR
Sep 1, 2026Returned to the company
Stock Option (Right to Buy)
−17,500$66.71$1.2M0 directFiling · EDGAR
Sep 1, 2026Returned to the company
Stock Option (Right to Buy)
−17,500$64.68$1.1M0 directFiling · EDGAR
Sep 1, 2026Returned to the company
Stock Option (Right to Buy)
−12,500$40.29$504K0 directFiling · EDGAR
Sep 1, 2026Returned to the company
Stock Option (Right to Buy)
−10,350$52.67$545K0 directFiling · EDGAR
Sep 1, 2026Returned to the company
Stock Option (Right to Buy)
−9,730$49.13$478K0 directFiling · EDGAR
Jun 18, 2026Grant or award from the company+5,925122,071 directFiling · EDGAR
Jun 18, 2026Grant or award from the company
Stock Option (Right to Buy)
+9,7309,730 directFiling · EDGAR

Dermata Therapeutics DRMA Director · filings 2021 to 2026

DateTransactionSharesPriceValueHeld afterSource
Jan 2, 2026Grant or award from the company
Stock Option (Right to Buy)
+2,5002,500 directFiling · EDGAR
Jan 13, 2025Grant or award from the company
Stock Option (Right to Buy)
+5,0005,000 directFiling · EDGAR
Jan 4, 2024Grant or award from the company
Stock Option (Right to Buy)
+10,00010,000 directFiling · EDGAR
Oct 6, 2022Grant or award from the company+20,65462,398 directFiling · EDGAR
Jul 7, 2022Grant or award from the company+18,11041,744 directFiling · EDGAR
Apr 7, 2022Grant or award from the company+10,59315,471 directFiling · EDGAR
Jan 3, 2022Grant or award from the company
Stock Option (right to buy)
+5,0005,000 directFiling · EDGAR
Aug 17, 2021Derivative converted+8,16313,041 directFiling · EDGAR
Aug 17, 2021Derivative converted
Series 1d Preferred Stock
−55,0780 directFiling · EDGAR

Ciphergen Biosystems Director · filings 2004 to 2005

DateTransactionSharesPriceValueHeld afterSource
Jun 8, 2005Grant or award from the company
Stock option (right to buy)
+12,50012,500 directFiling · EDGAR
Jun 8, 2005Grant or award from the company
Stock option (right to buy)
+13,00013,000 directFiling · EDGAR
Jun 3, 2004Grant or award from the company
Option to Purchase
+12,50012,500 directFiling · EDGAR
All 25 Forms 3, 4, 5 and 144
FiledFormCompanyLinks
Oct 20, 2026Form 4Cytokinetics CYTKFiling · EDGAR
Sep 1, 2026Form 4Crinetics Pharmaceuticals CRNXFiling · EDGAR
Jul 16, 2026Form 4Cytokinetics CYTKFiling · EDGAR
Jun 22, 2026Form 4Crinetics Pharmaceuticals CRNXFiling · EDGAR
May 27, 2026Form 4Cytokinetics CYTKFiling · EDGAR
May 5, 2026Form 144Cytokinetics CYTKFiling · EDGAR
May 5, 2026Form 4Cytokinetics CYTKFiling · EDGAR
Apr 15, 2026Form 4Cytokinetics CYTKFiling · EDGAR
Jan 16, 2026Form 4Cytokinetics CYTKFiling · EDGAR
Jan 6, 2026Form 4Dermata Therapeutics DRMAFiling · EDGAR
Dec 23, 2025Form 4Cytokinetics CYTKFiling · EDGAR
Dec 22, 2025Form 144Cytokinetics CYTKFiling · EDGAR
Oct 27, 2025Form 144Cytokinetics CYTKFiling · EDGAR
Oct 27, 2025Form 4Cytokinetics CYTKFiling · EDGAR
Oct 21, 2025Form 4Cytokinetics CYTKFiling · EDGAR
Jan 14, 2025Form 4Dermata Therapeutics DRMAFiling · EDGAR
Jan 5, 2024Form 4Dermata Therapeutics DRMAFiling · EDGAR
Oct 7, 2022Form 4Dermata Therapeutics DRMAFiling · EDGAR
Jul 8, 2022Form 4Dermata Therapeutics DRMAFiling · EDGAR
Apr 8, 2022Form 4Dermata Therapeutics DRMAFiling · EDGAR
Jan 5, 2022Form 4Dermata Therapeutics DRMAFiling · EDGAR
Aug 17, 2021Form 4Dermata Therapeutics DRMAFiling · EDGAR
Aug 12, 2021Form 3Dermata Therapeutics DRMAFiling · EDGAR
Jun 9, 2005Form 4Ciphergen BiosystemsFiling · EDGAR
Jun 7, 2004Form 4Ciphergen BiosystemsFiling · EDGAR

Every figure is as filed with the SEC on Forms 3, 4, 5 and 144. Holdings are the amounts reported after each person's latest filing at each company and can be out of date. Matching a Form 144 notice to Form 4 sales is SEC Tracker's inference from owner, company, dates and share counts, not something the filings state. Not investment advice. Not affiliated with the U.S. SEC.

Data on this page was fetched . The filing on SEC.gov is the record.